FUKUSHIMA et al., 1995 - Google Patents
Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in South VietnamFUKUSHIMA et al., 1995
View PDF- Document ID
- 1482226986235263003
- Author
- FUKUSHIMA Y
- TAKAHASHI H
- HALL W
- NAKASONE T
- NAKATA S
- SONG P
- DUC D
- HIEN B
- QUANG N
- TRINH T
- NISHIOKA K
- KITAMURA K
- KOMURO K
- VAHLNE A
- HONDA M
- Publication year
- Publication venue
- AIDS research and human retroviruses
External Links
Snippet
Serum specimens (n= 1899) were assayed for infections with HTLV-I, HTLV-II, and HIV-1 in seven classified groups of normal healthy controls, children, pregnant women, prostitutes, intravenous drug abusers, patients under going hemodialysis, and hemophiliacs in South …
- 239000003814 drug 0 title abstract description 14
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—AIDS or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FUKUSHIMA et al. | Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in South Vietnam | |
Barin et al. | Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients | |
Tedder et al. | Low prevalence in the UK of HTLV-I and HTLV-II infection in subjects with AIDS, with extended lymphadenopathy, and at risk of AIDS | |
Lillehoj et al. | Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide | |
Couroucé et al. | Seroepidemiology of HTLV-I/II in universal screening of blood donations in France | |
Wiktor et al. | Human T cell lymphotropic virus type I (HTLV-I) among female prostitutes in Kinshasa, Zaire | |
Cartier et al. | Southernmost carriers of HTLV‐I/II in the world | |
Anderson et al. | Transfusion-acquired human immunodeficiency virus infection among immunocompromised persons | |
Hartley et al. | Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays | |
US6242174B1 (en) | Discrimination between antibodies against HTLV-I, HTLV-II or related retroviruses, new peptides, detection of antibodies and immunoassay kits | |
Centers For Disease Control and Prevention and the USPHS Working Group. | Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II) | |
Brodine et al. | Simultaneous confirmation and differentiation of human T‐lymphotropic virus types I and II infection by modified Western blot containing recombinant envelope glycoproteins | |
Zanetti et al. | HTLV-II among Italian intravenous drug users and hemophiliacs | |
Medrano et al. | Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk | |
Lal et al. | Differential antibody responsiveness to p19 gag results in serological discrimination between human T lymphotropic virus type I and type II | |
Lal et al. | Identification of immunodominant epitopes in envelope glycoprotein of human T lymphotropic virus type II | |
LEE et al. | Seroepidemiology of human T-cell leukemia virus type-I in the Republic of Korea | |
Cardoso et al. | Seroprevalence of HTLV‐I in portugal and evidence of double retrovirus infection of a healthy donor | |
WO1992004046A1 (en) | Novel peptide antigens and immunoassays, test kits and vaccines using the same | |
Rudolph et al. | Discrimination of human T-lymphotropic virus type-I and type-II infections by synthetic peptides representing structural epitopes from the envelope glycoproteins | |
De Rivera et al. | Geographical clustering of human T-cell lymphotropic virus type 1 infection in Honduras | |
Schüpbach et al. | HTLV‐1 in Switzerland: Low prevalence of specific antibodies in HIV risk groups, high prevalence of cross‐reactive antibodies in normal blood donors | |
Blomberg et al. | Antibodies to human adult T cell leukaemia virus type I associated antigens in Swedish leukaemia patients and blood donors | |
Al-Mufti et al. | Seroprevalence of human T-cell leukemia/lymphoma virus type I and type II (HTLV-I/HTLV-II) infection among volunteer blood donors in Kuwait | |
WO1993002102A1 (en) | Novel peptide antigens and immunoassays, test kits and vaccines using the same |